Search
Felbamate
go.drugbank.com/drugs/DB00949ApprovedAlternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites. … In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization).
Hyaluronic acid
go.drugbank.com/drugs/DB08818ApprovedInvestigationalVet approvedHA is involved in many important physiological processes, including but not limited to wound healing, tissue regeneration, and joint lubrication. … [A230133] Several preparations of hyaluronic acid have been approved by the FDA and are available in oral, topical, and injectable forms.
Products: GO-ON, GO - ONAmphetamine
go.drugbank.com/drugs/DB00182ApprovedIllicitInvestigational[A18540] The first product of Smith, Kline and French was approved by the FDA on 1976.[L5194] During World War II, amphetamine was used to promote wakefulness in the soldiers. … After being proven to reduce drug-induced anesthesia and produce arousal and insomnia, amphetamine racemic mix was registered by Smith, Kline and French in 1935.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeGanaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636] … [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment
Pralidoxime
go.drugbank.com/drugs/DB00733ApprovedInvestigationalVet approvedIf given within 24 hours,after organophosphate exposure, pralidoxime reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase … Pralidoxime is an antidote to organophosphate pesticides and chemicals.
Levodopa
go.drugbank.com/drugs/DB01235ApprovedInvestigationalThe first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133]. … Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label].
Mixtures: LEVOCAENT-NX 100/25/200, LEVOCAENT-NX 100/25/200Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeChlorpromazine
go.drugbank.com/drugs/DB00477ApprovedInvestigationalVet approvedLike the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine, 3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-aminePotassium bicarbonate
go.drugbank.com/drugs/DB11098ApprovedInvestigationalIt is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. It is used in medicine as an antacid.
Mixtures: Neo KProducts: Effer-K Orange, Effer-K UnflavoredValsartan
go.drugbank.com/drugs/DB00177ApprovedInvestigationalARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling. … [A174154] By comparison, the angiotensin-converting enzyme inhibitor (ACEI) class of medications (which includes drugs such as [ramipril], [lisinopril], and [perindopril]) inhibit the conversion of
Mixtures: VARTERAL NF® 320 MG / 5 MG, VARTERAL NF® 320 MG / 5 MGCategories: Agents Acting on the Renin-Angiotensin SystemEnmetazobactam
go.drugbank.com/drugs/DB18716ApprovedInvestigational[A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections. … [L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.